Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2014 1
2015 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, Wasman J, Hartman P, Jesberger J, Dumadag L, Hohler E, Leeming R, Shenk R, Chen H, McCrae K, Dowlati A, Remick SC, Overmoyer B. Baar J, et al. Clin Cancer Res. 2009 May 15;15(10):3583-90. doi: 10.1158/1078-0432.CCR-08-2917. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417018 Free PMC article. Clinical Trial.
This randomized phase II trial was designed to evaluate the additional biomarker effect on angiogenesis when bevacizumab is added to docetaxel. EXPERIMENTAL DESIGN: Patients with inoperable breast cancer were randomized to either 2 cycles …
This randomized phase II trial was designed to evaluate the additional biomarker effect on angiogenesis when bevacizumab …
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthélémy P. Trédan O, et al. Target Oncol. 2015 Jun;10(2):189-98. doi: 10.1007/s11523-014-0334-9. Epub 2014 Sep 5. Target Oncol. 2015. PMID: 25185646 Review.
With emphasize on the research works of Jain et al., the aim of this review is to describe the impact of antivascular endothelial growth factor (VEGF) therapy on "pseudo-normalization" of tumor vasculature and tumor microenvironment, its role in early and metastatic bre …
With emphasize on the research works of Jain et al., the aim of this review is to describe the impact of antivascular endothelial gro …